SNY
Stock Details
SNY is Sanofi's stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 47.74$. Average daily volumn in 3 months 2.5M. Market cap 121.13B
Stock symbol : SNY. Exchange : NasdaqGS. Currency : USD Lastest price : 47.71$. Total volume : 2.26M. Market state POST Click reload if you want to check the lastest price on market!!!
Sanofi (SNY)
Last Price
47.71$Change
0.74Volume
2.26M
| Previous Close | 46.97 |
| Open | 47.70 |
| Day Range | 47.44-47.80 |
| Bid | 45.93 x 900 |
| Ask | 47.81 x 1.2k |
| Volume | 2.26M |
| Average Volume | 2.5M |
| Market Cap | 121.13B |
| Beta | 0.41 |
| 52 Week Range | 36.91-58.10 |
| Trailing P/E | 16.45 |
| Foward P/E | 9.58 |
| Dividend (Yield %) | 3.81% |
| Ex-Dividend Date | 2022-05-26 |
Financial Details
Organization
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines ... for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Market Cap:
121.13BRevenue:
45.39BTotal Assets:
124.58BTotal Cash:
12.74B
News about "Sanofi"
Sanofi renews social campaign to remind that vaccines let people ‘Dream Big’
Source from : ENDPOINTS NEWS - 11 hours ago
Sanofi is highlighting people's dreams — both big and small — to make the point that vaccines make them possible. The renewed “Dream Big” global social media campaign’s newest dreamer is Juan, a teach ...See details»
Sanofi (NASDAQ:SNY) Q4 2022 Earnings Call Transcript
Source from : Yahoo - 17 hours ago
Sanofi (NASDAQ:SNY) Q4 2022 Earnings Call Transcript February 3, 2023 Eva Schaefer-Jansen: find the slides to this earnings call on the Investors page of our website at sanofi.com. Moving to slide 3, ...See details»
Sanofi forecasts moderate profit growth on Dupixent demand
Source from : Reuters on MSN - 5 days ago
Sanofi forecast moderate earnings growth that undershot expectations, saying demand for bestselling asthma and eczema drug Dupixent would be partly offset by competition for its multiple sclerosis ...See details»
Sanofi stock dips as Q4 revenue grows but vaccine sales fall; Dupixent drives moderate profit outlook
Source from : Seeking Alpha on MSN - 5 days ago
Q4 sales grow on the back of blockbuster drug Dupixent but Vaccines business sees decline.The French pharma giant also provided FY23 outlook.Q4 Business EPS rose ...See details»
Sanofi: Increasing Our Long Position
Source from : Seeking Alpha - 5 days ago
Sanofi delivered a good set of numbers and Dupixent is well on track with our estimates. Click here to read our analysis why we think the stock is a buy.See details»
Sanofi profit narrowly beats forecasts, sees stronger earnings growth in 2023
Source from : MarketWatch on MSN - 6 days ago
DOW JONES NEWSWIRES Sanofi SA on Friday posted rising earnings and sales for the fourth quarter and said it expects its earnings per share to grow in 2023. The French pharma major ...See details»
Sanofi Drops as Generic Competition to Weigh on Profit
Source from : Bloomberg L.P. - 6 days ago
Sanofi declined to the lowest in more than two months after the French drugmaker forecast a slowdown in profit growth as generic competition ratchets up for multiple sclerosis drug Aubagio.See details»
Sanofi to let go of staff at vaccine plants in India as part of review
Source from : Yahoo News - 9 days ago
(Reuters) - French drugmaker Sanofi SA is reviewing operations at two of its vaccine making facilities in India and plans to let go of all employees at the plants, the company told Reuters, after it ...See details»
Sanofi Forecasts Lower Earnings Growth In 2023
Source from : Barron's - 5 days ago
French pharmaceutical giant Sanofi forecast slower earnings growth for 2023 on Friday after profits jumped in 2022 on the back of popular eczema and asthma drug Dupixent.See details»
Sanofi launches first global scholarship program for students from underrepresented communities pursuing careers in healthcare
Source from : Yahoo - 19 days ago
PARIS, Jan. 18, 2023 /PRNewswire/ -- Sanofi announces at the 53 rd Annual Meeting of the World Economic Forum in Davos the launch of the Sanofi NextGen Scholarship, its first global higher ...See details»
Sanofi picks Thread as sole provider of decentralized clinical trials for patient-focused platform
Source from : Outsourcing-pharma - 9 days ago
Thread is one of a number of companies that are trying to address persistent problems with clinical trials such as recruitment and retention through DCT platforms that loosen, and for some programs ...See details»
Press Release: Sanofi Ventures announces multi-year capital commitment from Sanofi, increasing evergreen fund to $750M
Source from : Benzinga.com - 28 days ago
Fund focuses on early stage investing, company co-creation, leading financing rounds and is committed to continuing its investment reach by prioritizing companies advancing innovation Sanofi ...See details»
Sanofi Upbeat on 2023 Earnings After 4Q Growth; Raises Dividend — Update
Source from : Morningstar%2c Inc. - 5 days ago
Sanofi SA on Friday posted rising earnings and sales for the fourth quarter, said it expects its earnings per share to grow in 2023, and raised its dividend for the year. The French pharma major ...See details»
Sanofi ADR
Source from : Wall Street Journal - 2 years ago
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...See details»